Gunzburg says antibody-based drug is effective against omicron

Developed by the Center for Gamaleya, a drug for the treatment of covid-19 based on monoclonal antibodies, is effective against the omicron strain, DIRECTOR of the institution Alexander Gintsburg said in an interview with RIA Novosti.

“The set of monoclonal antibodies has been tested on Omicron and works very well,” the scientist said. He also clarified that clinical trials are planned to start after the New Year holidays and be completed within three months.

In November, Deputy Director of the Center. Gamalei Denis Logunov said that the antibody-based drug is "in a high state of readiness" and expressed the hope that it will be approved in the coming months.

The drug is an analogue of the drug used to treat former US President Donald Trump when he contracted the CORONAVIRUS. This happened in the midst of the election race, when Trump was still HEAD of state and planned to stay for a second term. The president was prescribed remdesivir and the steroid drug dexamethasone. In addition, he was injected with an antibody cocktail manufactured by Regeneron Pharmaceuticals. Trump was released from the hospital four days later.